Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Wenting XuState Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Lingli ShiState Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-5673-970X
Aifang LuZheng's Gynecology Department, Kunshan Traditional Chinese Medicine Hospital, Suzhou, Jiangsu, China.
Lijuan CuiDepartment of Pathology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
Haiqing QianState Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Jiahui WangState Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Mengyu TangState Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Lihong WangState Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-7187-5910
Funding
Gusu Health Talent Plan Research Project GSWS2023016Innovation project of State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture NZYSKL240202Multi-centre Clinical Research Project Fund for Major Diseases of Suzhou DZXYJ202311National Natural Science Foundation of China 82575129Natural Science Foundation of Jiangsu province BK20221266Research Project of Jiangsu Society of Traditional Chinese Medicine PDJH2024046School-Land Collaborative Innovation Research Project of Jiangsu Pharmaceutical Vocational College 20239602School-Land Collaborative Innovation Research Project of Jiangsu Pharmaceutical Vocational College 202490608Science and Technology Development Plan of Suzhou SKY2023016Science and Technology Development Plan of Suzhou SYW2024009Science and Technology Program of Jiangsu Province BE2023734Youth Science and Technology Project of Suzhou KJXW2023063
6 · The paper itself
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a prevalent endocrine disorder, the molecular underpinnings of which remain largely undefined. The most common methylation modification of RNA, N
methodsWe utilized gene expression data and clinical information from the Gene Expression Omnibus database data sets GSE137684, GSE80432, and GSE114419. The expression of m6A-related genes was analyzed across all samples. Using the GSVA and CIBERSORT packages in R, we developed a diagnostic model based on the m6A gene-protein interaction network, conducted enrichment analysis of hub genes, and assessed the correlation between these genes and immune cell infiltration.
resultsAnalysis of data sets GSE137684 and GSE804322 identified variable expression patterns among three categories of m6A genes. A diagnostic model centered on m6A gene expression was established, highlighting five genes-WTAP, METTL14, ZC3H13, PCIF1, and RBM15-with significant effect coefficients. Unsupervised clustering of hub genes indicated that METTL14, HNRNPA2B1, YTHDF3, YTHDF2, YTHDC1, and YTHDC2 are potential discriminators in PCOS. The analysis of immune infiltration revealed a correlation between m6A regulators and immune cell levels, with METTL3 showing the most significant regulatory impact.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Intersection of m6A Methylation and Immune Response in PCOS: A Bioinformatics Perspective. · full record | OpenQuestion